Gabitril Seizure Warning Addresses Off-Label Use Of High Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston